A Phase III study of atopic dermatitis candidate nemolizumab, which enrolled people with moderate-to-severe pruritus, has achieved its primary endpoint.
Nemolizumab, a monoclonal antibody known also by its development name CIM331, is a subcutaneous anti-IL-31 biologic originally developed by Chugai Pharmaceutical (TYO: 4519).
The Japanese study was conducted by Maruho, which was granted development rights in the country under the terms of a 2016 deal with Chugai, which is majority-owned by Swiss pharma giant Roche (ROG: SIX).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze